100
Participants
Start Date
March 17, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
Focal Radiation therapy
Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
Pembrolizumab (200mg IV for 30 minutes
Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
CDX-301
Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
WITHDRAWN
Icahn School of Medicine at Mt Sinai, New York
RECRUITING
New York Presbyterian Hospital - Queens, New York
RECRUITING
Weill Cornell Medicine New York Presbyterian Hospital, New York
RECRUITING
Brooklyn Methodist Hospital - NewYork Presbyterian, New York
WITHDRAWN
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Houston Methodist Cancer Center, Houston
WITHDRAWN
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
UT Southwestern Medical Center, Dallas
Collaborators (1)
United States Department of Defense
FED
Merck Sharp & Dohme LLC
INDUSTRY
Celldex Therapeutics
INDUSTRY
Weill Medical College of Cornell University
OTHER